Randomized-controlled study of isophane and aspart insulin versus glargine and aspart insulin to treat prednisolone-induced hyperglycaemia in hospitalized patients

被引：0
|
作者：
Radhakutty, Anjana [1 ,2 ,3 ]
Stranks, Jessica L. [1 ]
Mangelsdorf, Brenda L. [1 ]
Drake, Sophie M. [1 ]
Roberts, Gregory W. [3 ,4 ]
Zimmermann, Anthony [2 ]
Stranks, Stephen N. [1 ]
Thompson, Campbell H. [3 ,5 ]
Burt, Morton G. [1 ,3 ]
机构：
[1] Repatriat Gen Hosp, Southern Adelaide Diabet & Endocrine Serv, Adelaide, SA, Australia
[2] Lyell McEwin Hosp, Endocrinol, Adelaide, SA, Australia
[3] Flinders Univ S Australia, Sch Med, Adelaide, SA, Australia
[4] Flinders Med Ctr, Dept Pharm, Adelaide, SA, Australia
[5] Univ Adelaide, Discipline Med, Adelaide, SA, Australia
来源：
CLINICAL ENDOCRINOLOGY | 2017年 / 86卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
174
引用
收藏
页码：22 / 22
页数：1
相关论文
共 50 条
  • [21] Insulin Glulisine Compared to Insulin Aspart and to Insulin Lispro Administered by Continuous Subcutaneous Insulin Infusion in Patients with Type 1 Diabetes: A Randomized Controlled Trial
    van Bon, Arianne C.
    Bode, Bruce W.
    Sert-Langeron, Caroline
    DeVries, J. Hans
    Charpentier, Guillaume
    DIABETES TECHNOLOGY & THERAPEUTICS, 2011, 13 (06) : 607 - 614
  • [22] Superior glycaemic control with once-daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial
    Onishi, Y.
    Ono, Y.
    Rabol, R.
    Endahl, L.
    Nakamura, S.
    DIABETES OBESITY & METABOLISM, 2013, 15 (09): : 826 - 832
  • [23] Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase III, open-label, 2:1 randomized, treat-to-target trial
    Yang, Wenying
    Ma, Jianhua
    Hong, Tianpei
    Liu, Ming
    Miao, Heng
    Peng, Yongde
    Wang, Changjiang
    Xu, Xiangjin
    Yang, Tao
    Nielsen, Anne M.
    Pan, Lili
    Liu, Weihong
    Zhao, Weigang
    DIABETES OBESITY & METABOLISM, 2019, 21 (07): : 1652 - 1660
  • [24] Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1)
    Garg, Satish K.
    Wernicke-Panten, Karin
    Wardecki, Marek
    Kramer, Daniel
    Delalande, Francois
    Franek, Edward
    Sadeharju, Karita
    Monchamp, Travis
    Mukherjee, Bhaswati
    Shah, Viral N.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2020, 22 (02) : 85 - 95
  • [25] Comparison of a Multiple Daily Insulin Injection Regimen (Glargine or Detemir Once Daily Plus Prandial Insulin Aspart) and Continuous Subcutaneous Insulin Infusion (Aspart) in Short-Term Intensive Insulin Therapy for Poorly Controlled Type 2 Diabetes Patients
    Lv, Wen-shan
    Li, Li
    Wen, Jun-ping
    Pan, Rong-fang
    Sun, Rui-xia
    Wang, Jing
    Xian, Yu-xin
    Cao, Cai-xia
    Gao, Yan-yan
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2013, 2013
  • [26] Insulintherapie einer prednisoloninduzierten HyperglykämieKrankenhausdaten einer randomisierten, kontrollierten StudieTreatment of prednisolone-induced hyperglycaemia in hospitalized patientsInsights from a randomized, controlled study
    M. Jecht
    Der Diabetologe, 2017, 13 (4): : 268 - 269
  • [27] INSULIN LISPRO WITH CONTINUOUS SUBCUTANEOUS INSULIN INFUSION IS SAFE AND EFFECTIVE IN PATIENTS WITH TYPE 2 DIABETES: A RANDOMIZED CROSSOVER TRIAL OF INSULIN LISPRO VERSUS INSULIN ASPART
    Thrasher, James
    Bhargava, Anuj
    Rees, Tina M.
    Wang, Tao
    Guzman, Cristina B.
    Glass, Leonard C.
    ENDOCRINE PRACTICE, 2015, 21 (03) : 247 - 257
  • [28] Treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin-naive type 2 diabetes patients: long-term effects on diabetesrelated complications
    Lammert, M
    Palmer, AJ
    Roze, S
    Valentine, WJ
    DIABETOLOGIA, 2005, 48 : A308 - A309
  • [29] Switching from glargine+insulin aspart to glargine+insulin aspart 30 before breakfast combined with exercise after dinner and dividing meals for the treatment of type 2 diabetes patients with poor glucose control – a prospective cohort study
    Jing Li
    Liming Wang
    Fen Chen
    Dongxia Xia
    Lingling Miao
    BMC Endocrine Disorders, 18
  • [30] Switching from glargine plus insulin aspart to glargine plus insulin aspart 30 before breakfast combined with exercise after dinner and dividing meals for the treatment of type 2 diabetes patients with poor glucose control - a prospective cohort study
    Li, Jing
    Wang, Liming
    Chen, Fen
    Xia, Dongxia
    Miao, Lingling
    BMC ENDOCRINE DISORDERS, 2018, 18
12345